Technical Analysis for IMGN - ImmunoGen, Inc.

Grade Last Price % Change Price Change
grade D 5.03 0.80% 0.04
IMGN closed up 0.8 percent on Thursday, January 17, 2019, on 80 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical IMGN trend table...

Date Alert Name Type % Chg
Jan 17 MACD Bearish Centerline Cross Bearish 0.00%
Jan 17 20 DMA Support Bullish 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 16 50 DMA Resistance Bearish 0.80%
Jan 16 180 Bearish Setup Bearish Swing Setup 0.80%
Jan 16 Outside Day Range Expansion 0.80%
Jan 16 Wide Bands Range Expansion 0.80%
Jan 15 50 DMA Resistance Bearish -4.55%
Jan 15 Doji - Bullish? Reversal -4.55%
Jan 15 Weak + Overbought Other -4.55%

Older signals for IMGN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

ImmunoGen, Inc. engages in the development of antibody-based anticancer therapeutics. The company develops its products using its targeted antibody payload (TAP) technology. Its product candidates include Trastuzumab emtansine, a Phase III clinical trial product for HER2+ metastatic breast cancer; lorvotuzumab mertansine, which is in Phase II clinical trial for the treatment of diagnosed metastatic small-cell lung cancer, as well as in a Phase I clinical trial for the treatment of multiple myeloma; IMGN853, a Phase I clinical trial product that targets over-expressed folate receptor 1 in ovarian cancer and other types of solid tumors, including non-small cell lung cancer; and IMGN529, a product in Phase I clinical trial for treatment of non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia. The company's compounds in earlier-stage of development comprise SAR3419, a Phase II clinical trial product to treat CD19-expressing B-cell malignancies, such as NHL and B-cell acute lymphoblastic leukemia; BT-062, a Phase I product, which targets CD138 antigen found on multiple myeloma and various solid tumors; SAR650984, a Phase I clinical trial product for CD38-targeting hematological malignancies; SAR566658, a Phase I clinical trial product for DS6-expressing solid tumors; BAY 94-9343, a Phase I clinical trial product for mesothelin-expressing solid tumors; and Amgen 1 and Amgen 2, which are phase I clinical trial compounds. It has collaborations with Amgen Inc.; Bayer HealthCare; Biotest AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; Genentech, Inc; Sanofi; and Hoffman-La Roche Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Is IMGN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 13.41
52 Week Low 3.8
Average Volume 2,664,432
200-Day Moving Average 8.5223
50-Day Moving Average 5.2836
20-Day Moving Average 4.874
10-Day Moving Average 5.297
Average True Range 0.3851
ADX 18.76
+DI 17.8883
-DI 21.4641
Chandelier Exit (Long, 3 ATRs ) 4.5447
Chandelier Exit (Short, 3 ATRs ) 4.9553
Upper Bollinger Band 5.8734
Lower Bollinger Band 3.8746
Percent B (%b) 0.58
BandWidth 41.009438
MACD Line -0.0075
MACD Signal Line -0.0579
MACD Histogram 0.0504
Fundamentals Value
Market Cap 450.68 Million
Num Shares 89.6 Million
EPS -1.22
Price-to-Earnings (P/E) Ratio -4.12
Price-to-Sales 5.58
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.48
Resistance 3 (R3) 5.46 5.29 5.41
Resistance 2 (R2) 5.29 5.18 5.30 5.38
Resistance 1 (R1) 5.16 5.10 5.23 5.18 5.35
Pivot Point 4.99 4.99 5.02 5.00 4.99
Support 1 (S1) 4.86 4.88 4.93 4.88 4.71
Support 2 (S2) 4.69 4.80 4.70 4.68
Support 3 (S3) 4.56 4.69 4.66
Support 4 (S4) 4.58